Skip Navigation

European Heart Journal 2002 23(18):1408-1411; doi:10.1053/euhj.2001.3270
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Antman, E.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Antman, E.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorials

‘I can see clearly now’: a new view on the use of IV GP IIb/IIIa inhibitors in acute coronary syndromes

E.M. Antman

Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, U.S.A.

References

  1. Roffi M, Chew DP, Mukherjee D. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes: gradient of benefit related to the revascularization strategy. Eur Heart J. 2002;23:1441–1448[Abstract/Free Full Text]
  2. N Engl J Med. 1998;338:1498–1505[Abstract/Free Full Text]
  3. N Engl J Med. 1998;338:1488–1497[Abstract/Free Full Text]
  4. Circulation. 1998;97:2386–2395[Abstract/Free Full Text]
  5. N Engl J Med. 1998;339:436–443[Abstract/Free Full Text]
  6. Circulation. 2002;105:316–321[Abstract/Free Full Text]
  7. Lancet. 2001;357:1915–1924[CrossRef][Web of Science][Medline]
  8. N Engl J Med. 1994;330:956–961[Abstract/Free Full Text]
  9. N Engl J Med. 1997;336:1689–1696[Abstract/Free Full Text]
  10. Lancet. 1997;349:1429–1435[CrossRef][Web of Science][Medline]
  11. Lancet. 1997;349:1422–1428[CrossRef][Web of Science][Medline]
  12. Circulation. 1997;96:1445–1453[Abstract/Free Full Text]
  13. Braunwald, E, Antman, EM, Beasley, JW, ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina), http://www.acc.org/clinical/guidelines/unstable/unstable.pdf, 2002
  14. Boersma E, Harrington RA, Moliterno DJ. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359:189–198[CrossRef][Web of Science][Medline]
  15. Kleiman NS, Lincoff AM, Flaker GC. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation. 2000;101:751–757[Abstract/Free Full Text]
  16. Boersma E, Akkerhuis KM, Theroux P, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation. 1999;100:2045–2048[Abstract/Free Full Text]
  17. Cannon CP, Weintraub WS, Demopoulos LA. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879–1887[Abstract/Free Full Text]
  18. Antman EM. Troponin measurements in ischemic heart disease: more than just a black and white picture. J Am Coll Cardiol. 2001;38:987–990[Free Full Text]
  19. N Engl J Med. 2001;345:494–502[Abstract/Free Full Text]
  20. Antman EM, Cohen M, Radley D. Assessment of the treatment effect of enoxaparin for unstable angina/ non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation. 1999;100:1602–1608[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
R. Glaser, H. A. Glick, H. C. Herrmann, and S. E. Kimmel
The Role of Risk Stratification in the Decision to Provide Upstream Versus Selective Glycoprotein IIb/IIIa Inhibitors for Acute Coronary Syndromes: A Cost-Effectiveness Analysis
J. Am. Coll. Cardiol., February 7, 2006; 47(3): 529 - 537.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
K. S. Pieper, A. A. Tsiatis, M. Davidian, V. Hasselblad, N. S. Kleiman, E. Boersma, W.-C. Chang, J. Griffin, P. W. Armstrong, R. M. Califf, et al.
Differential Treatment Benefit of Platelet Glycoprotein IIb/IIIa Inhibition With Percutaneous Coronary Intervention Versus Medical Therapy for Acute Coronary Syndromes: Exploration of Methods
Circulation, February 10, 2004; 109(5): 641 - 646.
[Abstract] [Full Text] [PDF]

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Antman, E.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Antman, E.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?